Clinical trials: Liver Diseases
Chronic Hepatitis C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin…
- Trial name
- NCT01517308
- Testing
- pegylated interferon alpha 2a + ribavirin
- Where
- Italy
- Sponsor
- Federico II University
Hepatitis C, Hiv
Zepatier in Patients with Substance Use
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or…
- Conditions
- Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
- Trial name
- NCT04048850
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
End-Stage Liver Diseases
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06984497
- Testing
- Infusion of umbilical cord-mesenchymal stem cells through peripheral veins, Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- General Hospital of Shenyang Military Region
Liver Dysfunction
Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion
This study is a multicenter, single-arm, open-label, 24 weeks, and investigator-initiated clinical trial to assess the influence of CYP3A5 polymorphism on liver function abnormality and the trough level change after conversion to…
- Trial name
- NCT02882113
- Testing
- Advagraf
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Hepatitis C, Cirrhosis
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
Direct-acting antiviral agents (DAAs) targeting HCV have revolutionized the treatment of HCV. The efficacy of DAA-based therapy can depend on patient-related factors such as treatment experience, cirrhosis, but also on viral…
- Trial name
- NCT05467826
- Testing
- Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Esophageal and Gastric Varices
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy
In the Western world, liver cirrhosis is a significant issue. Acute variceal bleeding (AVB) is a considerable complication of cirrhosis associated with high mortality.
- Trial name
- NCT05331768
- Testing
- banding ligation plus terlipressin infusion
- Where
- Mexico
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Metastatic Colorectal Cancer
Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
This study is for patients with metastatic colorectal cancer who are candidates for resection of metastases. This study will be conducted sequentially with 2 cohorts: 1.) Monotherapy Cohort and 2.) Combination Cohort…
- Trial name
- ATELIER (NCT03340558)
- Testing
- Atezolizumab, Cobimetinib
- Where
- United States
- Sponsor
- Niharika Mettu
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Colorectal Cancer Metastatic, Colorectal Cancer
TheraSphere® For Treatment of Metastases in Liver
To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.
- Trial name
- NCT04517643
- Testing
- Therasphere Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cirrhosis, Myosteatosis
Protocol for Muscle Attenuation Cut-offs in Cirrhosis
The goal of this observational study is to learn if new muscle attenuation cut-offs for the definition of myosteatosis can better predict survival in patients with cirrhosis.
- Conditions
- Cirrhosis, Myosteatosis, Sarcopenia, Sarcopenia in Liver Cirrhosis
- Trial name
- Myocirrhosis (NCT06593015)
- Testing
- Radiological tool for the diagnosis of myosteatosis
- Where
- Italy
- Volunteers
- 1,296 people
- Sponsor
- University of Roma La Sapienza
Hepatitis B, Chronic
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients
This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.
- Trial name
- NCT02327676
- Testing
- Emtricitabine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing
Liver Cirrhosis, Sarcopenia
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.
- Trial name
- NCT04874350
- Testing
- LPCN 1148
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Lipocine Inc.
Sepsis, Septic Shock
Central Venous Catheter Colonisation Among Critically Ill Patients in Intensive Care Units
Background: Central Venous catheter insertion technique and indwelling time are major risk factors for CVC colonisation. Colonisation occurs through microbial migration and biofilm formation along the catheter insertion tract.
- Conditions
- Sepsis, Septic Shock, Post-cardiac Surgery, Post-Cardiorespiratory Arrest Coma
- Trial name
- NCT03270774
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Makerere University
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC)
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
- Trial name
- NCT03419897
- Testing
- Tislelizumab
- Where
- 54 sites in China, France and 6 more
- Volunteers
- 249 people
- Sponsor
- BeiGene
Cancer
Physician Liver Function Test (LFT) Monitoring for Tykerb Pts
In July 2008, the lapatinib (Tykerb) Prescribing Information (label) was updated to include a boxed warning related to hepatotoxcity and detailed instructions for monitoring liver function before and during lapatanib exposure.
- Trial name
- NCT01462552
- Testing
- Lapatanib
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
HepatoCellular Carcinoma, Cirrhosis
Mutational Landscape in Hepatocellular Carcinoma
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of…
- Trial name
- MUTHEC (NCT03071458)
- Where
- France
- Volunteers
- 808 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.